

REMARKS

Currently Claims 1-14 are pending. Claims 9, 10, 13, and 14 have been canceled without prejudice to the filing of a continuing application thereon. Claims 6, 7, 8, 11, and 12 have been amended to reduce the filing fee by removing multiple dependencies.

Claim 1 has been amended to delete the recitation of "methylene" in the description of the R_c moiety. Claim 1 has also been amended to delete the recitations "(which may be in either the α or β configuration)" that follow the recitation of "methyl" in the description of R_c , as it is clear from the recitation of "methyl" itself that it could be in either the α or β configuration and thus the deleted recitations were redundant over the recitation of "methyl" itself. Claim 1 has also been amended to place the recitations of propellants in a proper Markush group format and correct a typographical error in the recitation of "1,1,1,2,3,3,3-heptofluoro-n-propane," which was inadvertently recited as "1,1,1,2,3,3,3-heterofluoro-n-propane."

Claim 2 has been canceled and rewritten in independent form as new claim 15. Claim 3 has been canceled and rewritten in independent form as claims 17 and 29. Claim 4 has been canceled and rewritten in independent form as claims 21 and 33. Claim 5 has been canceled and rewritten in independent form as claims 25 and 37. The subject matter from several of the multiple dependencies that were deleted from claim 6 has been recited in new dependent claims 16, 18, 22, 26, 30, 34, and 38. The subject matter from several of the multiple dependencies that were deleted from claim 11 has been recited in new dependent claims 19, 23, 27, 31, 35, and 39. The subject matter from several of the multiple dependencies that were deleted from claim 11 has been recited in new dependent claims 20, 24, 28, 32, 36, and 40.

The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed application.


Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance forthwith.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Date: March 21, 2006
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988

Respectfully submitted:


J. Michael Strickland
Attorney for Applicants
Reg. No. 47,115